Live Breaking News & Updates on Active Psoriatic Arthritis

Stay updated with breaking news from Active psoriatic arthritis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors

Guselkumab, Risankizumab Boast Longest Drug Survival Among IL-17, IL-23 Inhibitors
hcplive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hcplive.com Daily Mail and Mail on Sunday newspapers.

Falal Cosentyx Secukinumab , Cochrane Library , Health Drug , Radboud University Medical Center , International Psoriasis Council Juul , International Psoriasis Council , Radboud University Medical Centre , Systematic Review , Antagonist Receives , Moderate To Severe Plaque , Spec Feature , First Selective , Active Psoriatic Arthritis , Expert Rev Clin ,

Risankizumab Shows Efficacy in Patients With Active Psoriatic Arthritis Through 52 Weeks

Efficacy results support long-term use of risankizumab in patients with active psoriatic arthritis across multiple patient and psoriatic disease characteristics. ....

American College Of Rheumatology , American College , Psoriasis Area Severity Index , Minimal Disease Activity , Low Disease Activity , Risankizumab Efficacy , Active Psoriatic Arthritis ,

Risankizumab Effective Through 100 Weeks in Improving Signs, Symptoms of Psoriatic Arthritis

These data suggest risankizumab was both safe and efficacious through 100 weeks for PsA patients, with no new safety signals.
....

South Australia , Monash University Department , American College Of Rheumatology , Monash University , American College , Active Psoriatic Arthritis , Week Results , Rheumatol Ther , Psoriatic Arthritis , 100 Weeks ,

Ryan DeMasi, MD: Long-Term Safety, Efficacy of Risankizumab in Patients with Psoriatic Arthritis

The 148-week study evaluated multiple domains of patients with psoriatic arthritis receiving risankizumab treatment, providing insights into patients' improvement over time. ....

United States , San Diego , Ryan Demasi , America College Of Rheumatology Convergence , American College Of Rheumatology , Term Efficacy , Active Psoriatic Arthritis , Week Results , American College , America College , Rheumatology Convergence ,

UPJOINT: Upadacitinib Demonstrates Efficacy, Safety in Interim Analysis

An interim analysis from the UPJOINT trial provides insight into the effects of upadacitinib use in real-world settings among patients with oligo- or polyarticular psoriatic arthritis. ....

Axel Hueber , Drug Administration , Division Of Rheumatology At Paracelsus Medical University , Paracelsus Medical University , Active Psoriatic Arthritis , Safety Data , Observational Study , Clinical Practice , Activa Psa , Psoriatic Arthritis , Upadacitinib Rinvoq ,